Skip to main content

Modification of risk for subsequent cancer after female breast cancer by a family history of breast cancer

Breast Cancer Research and Treatment volume 111, pages 165–169 (2008)Cite this article

Abstract

An increased risk of second primary cancers may depend on many reasons, including therapy for the first cancer and heritable causation. Population level data are not available exploring the risks of subsequent cancers after breast cancer considering a familial history of breast cancers. We used the nation-wide Swedish Family-Cancer Database to investigate such risks, based on 43,398 first invasive female breast cancers. Standardized incidence ratios (SIRs) were calculated for the second cancer after breast cancer using rates for first cancer as a reference. Many cancers at discordant sites were increased after breast cancer. SIRs for subsequent neoplasms in women who had a family history of breast cancer were increased for ovarian (2.0) and endometrial (1.8) cancers and for acute lymphoid leukemia (12.7) and myelofibrosis (9.4). The data suggest that the familial aggregation of breast and endometrial cancers may be explained by yet unidentified heritable causes. The remarkably high risks for second acute lymphoid leukemia and myelofibrosis, both characterized by chromosomal aberrations, in women with a family history of breast cancer may signal heritable defects in the ability to process DNA damage caused by ionizing radiation and chemotherapy.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

Abbreviations

SIRs:

Standardized incidence ratios

SEER:

Surveillance, epidemiology and end results

References

  1. Travis LB (2006) The epidemiology of second primary cancers. Cancer Epidemiol Biomarkers Prev 15:2020–2026

    PubMed  Article  Google Scholar 

  2. Travis LB, Rabkin CS, Brown LM, Allan JM, Alter BP, Ambrosone CB et al (2006) Cancer survivorship−genetic susceptibility and second primary cancers: research strategies and recommendations. J Natl Cancer Inst 98:15–25

    PubMed  Google Scholar 

  3. Hemminki K, Boffetta P (2004) Multiple primary cancers as clues of environmental and heritable courses of cancer and of mechanisms of carcinogenesis. IARC Sci Publ 157:289–297

    PubMed  Google Scholar 

  4. Dong C, Hemminki K (2001) Second primary neoplasms in 633964 cancer patients in Sweden, 1958–1996. Int J Cancer 93:155–161

    PubMed  Article  CAS  Google Scholar 

  5. Brennan P, Scelo G, Hemminki K, Mellemkjaer L, Tracey E, Andersen A et al (2005) Second primary cancers among 109 000 cases of non-Hodgkin’s lymphoma. Br J Cancer 93:159–166

    PubMed  Article  CAS  Google Scholar 

  6. Hemminki K, Scelo G, Boffetta P, Mellemkjaer L, Tracey E, Andersen A et al (2005) Second primary malignancies in patients with male breast cancer. Br J Cancer 92:1288–1292

    PubMed  Article  CAS  Google Scholar 

  7. Mellemkjaer L, Friis S, Olsen JH, Scelo G, Hemminki K, Tracey E et al (2006) Risk of second cancer among women with breast cancer. Int J Cancer 118:2285–2292

    PubMed  Article  CAS  Google Scholar 

  8. Chappuis P, Rosenblatt J, Foulkes W (1999) The influence of familial and hereditary factors on the prognosis of breast cancer. Ann Oncol 10:1163–1170

    PubMed  Article  CAS  Google Scholar 

  9. Vaittinen P, Hemminki K (2000) Risk factors and age-incidence relationships for contralateral breast cancer. Int J Cancer 88:998–1002

    PubMed  Article  CAS  Google Scholar 

  10. Hartman M, Czene K, Reilly M, Bergh J, Lagiou P, Trichopoulos D et al (2005) Genetic implications of bilateral breast cancer: a population based cohort study. Lancet Oncol 6:377–382

    PubMed  Article  Google Scholar 

  11. Hemminki K, Ji J, Forsti A (2007) Risks for familial and contralateral breast cancer interact multiplicatively and cause a high risk. Cancer Res 67:868–870

    PubMed  Article  CAS  Google Scholar 

  12. Johnson N, Fletcher O, Naceur-Lombardelli C, dos Santos Silva I, Ashworth A, Peto J (2005) Interaction between CHEK2*1100delC and other low-penetrance breast-cancer susceptibility genes: a familial study. Lancet 366:1554–1557

    PubMed  Article  CAS  Google Scholar 

  13. Johnson N, Fletcher O, Palles C, Rudd M, Webb E, Sellick G et al (2007) Counting potentially functional variants in BRCA1, BRCA2 and ATM predicts breast cancer susceptibility. Hum Mol Genet 16:1051–1057

    PubMed  Article  CAS  Google Scholar 

  14. Pal T, Flanders T, Mitchell-Lehman M, MacMillan A, Brunet J, Narod S et al (1998) Genetic implications of double primary cancers of the colorectum and endometrium. J Med Genet 35:978–984

    PubMed  CAS  Article  Google Scholar 

  15. Hemminki K, Vaittinen P, Easton D (2000) Familial cancer risks to offspring from mothers with two primary breast cancers: leads to cancer syndromes. Int J Cancer 88:87–91

    PubMed  Article  CAS  Google Scholar 

  16. Hemminki K, Granström C, Sundquist J, Lorenzo Bermejo J (2006) The updated Swedish family-cancer database used to assess familial risks of prostate cancer during rapidly increasing incidence. Heredit Cancer Clin Pract 4:186–192

    Article  Google Scholar 

  17. Centre for Epidemiology (2007) Cancer incidence in Sweden 2005. The National Board of Health and Welfare, Stockholm

    Google Scholar 

  18. Antoniou A, Pharoah PD, Narod S, Risch HA, Eyfjord JE, Hopper JL et al (2003) Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 72:1117–1130

    PubMed  Article  CAS  Google Scholar 

  19. Chen S, Iversen ES, Friebel T, Finkelstein D, Weber BL, Eisen A et al (2006) Characterization of BRCA1 and BRCA2 mutations in a large United States sample. J Clin Oncol 24:863–871

    PubMed  Article  CAS  Google Scholar 

  20. The Breast Cancer Linkage Consortium (1999) Cancer risks in BRCA2 mutation carriers. J Natl Cancer Inst 91(91):1310–1316

    Article  Google Scholar 

  21. Thompson D, Easton DF (2002) Cancer Incidence in BRCA1 mutation carriers. J Natl Cancer Inst 94:1358–1365

    PubMed  CAS  Google Scholar 

  22. Risch HA, McLaughlin JR, Cole DE, Rosen B, Bradley L, Fan I et al (2006) Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada. J Natl Cancer Inst 98:1694–1706

    PubMed  CAS  Article  Google Scholar 

  23. Lorenzo Bermejo J, Hemminki K (2004) Familial association of histology specific breast cancers with cancers at other sites. Int J Cancer 109:430–435

    PubMed  Article  CAS  Google Scholar 

  24. Lorenzo Bermejo J, Buchner FL, Hemminki K (2004) Familial risk of endometrial cancer after exclusion of families that fulfilled Amsterdam, Japanese or Bethesda criteria for HNPCC Ann Oncol 15:598–604

    PubMed  Article  CAS  Google Scholar 

  25. Lynch HT, de la Chapelle A (2003) Hereditary colorectal cancer. N Engl J Med 348:919–932

    PubMed  Article  CAS  Google Scholar 

  26. Jaffe E, Harris N, Stein H, Vardiman J (2001) Pathology and genetics of tumours of haematopoietic and lymphoid tissues. IARC, Lyon

    Google Scholar 

  27. Cybulski C, Gorski B, Huzarski T, Masojc B, Mierzejewski M, Debniak T et al (2004) CHEK2 is a multiorgan cancer susceptibility gene. Am J Hum Genet 75:1131–1135

    PubMed  Article  CAS  Google Scholar 

  28. Meijers-Heijboer H, Wijnen J, Vasen H, Wasielewski M, Wagner A, Hollestelle A et al (2003) The CHEK2 1100delC mutation identifies families with a hereditary breast and colorectal cancer phenotype. Am J Hum Genet 72:1308–1314

    PubMed  Article  CAS  Google Scholar 

  29. Erkko H, Xia B, Nikkila J, Schleutker J, Syrjakoski K, Mannermaa A et al (2007) A recurrent mutation in PALB2 in Finnish cancer families. Nature 446:316–319

    PubMed  Article  CAS  Google Scholar 

  30. Renwick A, Thompson D, Seal S, Kelly P, Chagtai T, Ahmed M et al (2006) ATM mutations that cause ataxia-telangiectasia are breast cancer susceptibility alleles. Nat Genet 38:873–875

    PubMed  Article  CAS  Google Scholar 

  31. Seal S, Thompson D, Renwick A, Elliott A, Kelly P, Barfoot R et al (2006) Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles. Nat Genet 38:1239–1241

    PubMed  Article  CAS  Google Scholar 

  32. Steffen J, Nowakowska D, Niwinska A, Czapczak D, Kluska A, Piatkowska M et al (2006) Germline mutations 657del5 of the NBS1 gene contribute significantly to the incidence of breast cancer in Central Poland. Int J Cancer 119:472–475

    PubMed  Article  CAS  Google Scholar 

Download references

Acknowledgements

Supported by Deutsche Krebshilfe, the Swedish Cancer Society, the EU, LSHC-CT-2004-503465 and the Swedish Council for Working Life and Social Research. The Family-Cancer Database was created by linking registers maintained at Statistics Sweden and the Swedish Cancer Registry.

Author information

Affiliations

  1. Division of Molecular Genetic Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany

    Kari Hemminki, Hui Zhang & Justo Lorenzo Bermejo

  2. Center for Family and Community Medicine, Karolinska Institute, Alfred Nobels alle 12, Huddinge, 14183, Sweden

    Kari Hemminki & Jan Sundquist

Authors
  1. Kari Hemminki
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hui Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jan Sundquist
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Justo Lorenzo Bermejo
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kari Hemminki.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Hemminki, K., Zhang, H., Sundquist, J. et al. Modification of risk for subsequent cancer after female breast cancer by a family history of breast cancer. Breast Cancer Res Treat 111, 165–169 (2008). https://doi.org/10.1007/s10549-007-9759-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10549-007-9759-5

Keywords

  • Familial breast cancer
  • Multiple primaries
  • Heredity
  • Genetic risk
  • Leukemia